Topokine Therapeutics Secures New Round of Capital to Advance Clinical Development of Facial Aesthetics Products
BOSTON, Mass., April 2, 2014-- Topokine Therapeutics, a clinical-stage biotechnology company developing topical medications for non-invasive contouring of the face and body, announced that it has received a new round of venture financing from Schooner Capital, a Boston-based investment firm. Specific terms were not disclosed.
"We continue to be impressed by Topokine's scientific data and clinical advances," said Ted Henderson, a Managing Director at Schooner Capital. "We see a substantial untapped market for topical contouring therapies and believe that Topokine's products, if approved, will be game-changing for facial aesthetics."
"We are pleased to receive additional funding from Schooner Capital," said Murat Kalayoglu, MD, PhD, Topokine President and CEO. "This new round will help advance our growing clinical pipeline and expand our worldwide intellectual property position."
Topokine Therapeutics is a clinical-stage biotechnology company developing topical medications for non-invasive contouring of the face and body. The company's lead program, XAF5 Gel, is a topical adipomodulatory product in Phase 2 clinical development for local reduction of excess submental fat ("double chin") and other indications. Topokine's pipeline also includes XOPH5 Ointment to treat steatoblepharon ("eye bags") and TAT4, a topical "filler" therapy to increase local tissue volume.
About Schooner Capital
Founded in 1971, Schooner Capital is a Boston-based private investment firm. The firm approaches all investments with a long-term perspective and invests in private companies across stage and sector, with a focus on quality of management, unit economics, and long-term growth prospects.
This press release contains forward-looking statements. These statements are based on current beliefs and expectations, but actual results may differ.
Topokine Therapeutics, Inc.
Venture Capital Database